Last reviewed · How we verify

Racemic Albuterol

Sumitomo Pharma America, Inc. · Phase 3 active Small molecule

Racemic Albuterol is a Beta-2 adrenergic agonist (short-acting) Small molecule drug developed by Sumitomo Pharma America, Inc.. It is currently in Phase 3 development for Acute bronchospasm relief in asthma, Acute bronchospasm relief in chronic obstructive pulmonary disease (COPD). Also known as: Ventolin Inhalation Solution.

Racemic albuterol is a beta-2 adrenergic agonist that relaxes airway smooth muscle to improve breathing.

Racemic albuterol is a beta-2 adrenergic agonist that relaxes airway smooth muscle to improve breathing. Used for Acute bronchospasm relief in asthma, Acute bronchospasm relief in chronic obstructive pulmonary disease (COPD).

At a glance

Generic nameRacemic Albuterol
Also known asVentolin Inhalation Solution
SponsorSumitomo Pharma America, Inc.
Drug classBeta-2 adrenergic agonist (short-acting)
TargetBeta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaRespiratory
PhasePhase 3

Mechanism of action

Albuterol binds to beta-2 adrenergic receptors on bronchial smooth muscle, activating intracellular signaling that increases cAMP levels and causes bronchodilation. The racemic mixture contains both R- and S-enantiomers; the R-enantiomer is the active form, while the S-enantiomer may contribute to airway hyperresponsiveness. It is used as a rapid-acting bronchodilator for acute relief of bronchoconstriction in asthma and COPD.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Racemic Albuterol

What is Racemic Albuterol?

Racemic Albuterol is a Beta-2 adrenergic agonist (short-acting) drug developed by Sumitomo Pharma America, Inc., indicated for Acute bronchospasm relief in asthma, Acute bronchospasm relief in chronic obstructive pulmonary disease (COPD).

How does Racemic Albuterol work?

Racemic albuterol is a beta-2 adrenergic agonist that relaxes airway smooth muscle to improve breathing.

What is Racemic Albuterol used for?

Racemic Albuterol is indicated for Acute bronchospasm relief in asthma, Acute bronchospasm relief in chronic obstructive pulmonary disease (COPD).

Who makes Racemic Albuterol?

Racemic Albuterol is developed by Sumitomo Pharma America, Inc. (see full Sumitomo Pharma America, Inc. pipeline at /company/sumitomo-pharma-america-inc).

Is Racemic Albuterol also known as anything else?

Racemic Albuterol is also known as Ventolin Inhalation Solution.

What drug class is Racemic Albuterol in?

Racemic Albuterol belongs to the Beta-2 adrenergic agonist (short-acting) class. See all Beta-2 adrenergic agonist (short-acting) drugs at /class/beta-2-adrenergic-agonist-short-acting.

What development phase is Racemic Albuterol in?

Racemic Albuterol is in Phase 3.

What are the side effects of Racemic Albuterol?

Common side effects of Racemic Albuterol include Tremor, Headache, Nervousness, Palpitations, Muscle cramps, Tachycardia.

What does Racemic Albuterol target?

Racemic Albuterol targets Beta-2 adrenergic receptor and is a Beta-2 adrenergic agonist (short-acting).

Related